These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Drugs for MRSA with reduced susceptibility to vancomycin. Med Lett Drugs Ther; 2009 May 04; 51(1311):36; quiz 37. PubMed ID: 19417720 [No Abstract] [Full Text] [Related]
6. Two new drugs join the war on superbugs. Mayo Clin Health Lett; 2000 Oct 04; 18(10):4. PubMed ID: 11019686 [No Abstract] [Full Text] [Related]
7. Antimicrobial symposium. Part VIII. Glycopeptides, oxazolidinones, and lipopeptides. Hoffman-Roberts HL, Obritsch MD, Bronze MS, Greenfield RA. J Okla State Med Assoc; 2007 Apr 04; 100(4):105-11. PubMed ID: 17476993 [No Abstract] [Full Text] [Related]
8. Development of decreased susceptibility to daptomycin and vancomycin in a Staphylococcus aureus strain during prolonged therapy. Mariani PG, Sader HS, Jones RN. J Antimicrob Chemother; 2006 Aug 04; 58(2):481-3. PubMed ID: 16847029 [No Abstract] [Full Text] [Related]
9. New drugs for Gram-positive uropathogens. Wagenlehner FM, Naber KG. Int J Antimicrob Agents; 2004 Sep 04; 24 Suppl 1():S39-43. PubMed ID: 15364305 [Abstract] [Full Text] [Related]
11. Combating the growing problem of methicillin-resistant Staphylococcus aureus: do the newer antibiotics represent a better alternative to vancomycin? Chambers HF, Hegde SS. Expert Rev Anti Infect Ther; 2007 Jun 04; 5(3):333-5. PubMed ID: 17547497 [No Abstract] [Full Text] [Related]
12. Linezolid. Narang M, Gomber S. Indian Pediatr; 2004 Nov 04; 41(11):1129-32. PubMed ID: 15591662 [Abstract] [Full Text] [Related]
13. Therapeutic challenges in the era of antibiotic resistance. Lee C. Int J Antimicrob Agents; 2008 Dec 04; 32 Suppl 4():S197-9. PubMed ID: 19134519 [Abstract] [Full Text] [Related]
14. Linezolid better than vancomycin in treating drug-resistant pneumonia. Rollins G. Rep Med Guidel Outcomes Res; 2004 Apr 02; 15(7):1, 6-7. PubMed ID: 15101393 [No Abstract] [Full Text] [Related]
15. [New antibacterial agents]. Järvinen A, Valtonen V. Duodecim; 2000 Apr 02; 116(24):2803-5. PubMed ID: 12077883 [No Abstract] [Full Text] [Related]
16. [Linezolid: antibacterial activity, clinical efficacy and resistance]. Bourgeois-Nicolaos N, Piriou O, Butel MJ, Doucet-Populaire F. Ann Biol Clin (Paris); 2006 Apr 02; 64(6):549-64. PubMed ID: 17162258 [Abstract] [Full Text] [Related]
17. In vitro activity of daptomycin against clinical isolates with reduced susceptibilities to linezolid and quinupristin/dalfopristin. Anastasiou DM, Thorne GM, Luperchio SA, Alder JD. Int J Antimicrob Agents; 2006 Nov 02; 28(5):385-8. PubMed ID: 17046205 [Abstract] [Full Text] [Related]
18. Bacteremia and infective endocarditis caused by a non-daptomycin-susceptible, vancomycin-intermediate, and methicillin-resistant Staphylococcus aureus strain in Taiwan. Huang YT, Hsiao CH, Liao CH, Lee CW, Hsueh PR. J Clin Microbiol; 2008 Mar 02; 46(3):1132-6. PubMed ID: 18199793 [Abstract] [Full Text] [Related]